Rallybio Holdings LLC (RLYB) News

Form 8-K - Current report

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT – –...

Rallybio to Present at Upcoming Investor Conferences

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

– On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 – – $88.6 Million in Cash...

Form 8-K - Current report

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities